Invivyd (IVVD) Depreciation & Amortization (CF) (2021 - 2025)
Invivyd (IVVD) reported Depreciation & Amortization (CF) of $149000.0 for Q4 2025, down 86.25% on a YoY basis from $1.1 million in Q4 2024, and little changed quarter-over-quarter from $149000.0 in Q3 2025.
Invivyd (IVVD) Depreciation & Amortization (CF) (2021 - 2025) Analysis & Trends
Invivyd has reported Depreciation & Amortization (CF) for 5 years, with the latest figure at $149000.0 in Q4 2025.
- For the quarter ending Q4 2025, Depreciation & Amortization (CF) fell 86.25% year-over-year to $149000.0; the trailing twelve-month figure through Dec 2025 stood at $755000.0 (down 48.5% YoY), and the FY2025 full-year result was $755000.0, down 48.5% from the prior year.
- Depreciation & Amortization (CF) for Q4 2025 stood at $149000.0, roughly flat from $149000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $1.1 million in Q4 2024, with the low at $1000.0 in Q4 2021.
- Historically, Depreciation & Amortization (CF) has averaged $161352.9 across 5 years, with a median of $121000.0 in 2023.
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) soared 2900.0% — and 2025, when it sank 86.25%.
- Invivyd's Depreciation & Amortization (CF) stood at $1000.0 in 2021, then surged by 2600.0% to $27000.0 in 2022, then surged by 344.44% to $120000.0 in 2023, then surged by 803.33% to $1.1 million in 2024, then slumped by 86.25% to $149000.0 in 2025.
- The last three Depreciation & Amortization (CF) figures came in at $149000.0 (Q4 2025), $149000.0 (Q3 2025), and $151000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Invivyd | 168.41 Mn | -58.28 Mn | - | 149,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 149,000.00 |
| Dec 31, 2025 | 149,000.00 |
| Sep 30, 2025 | 149,000.00 |
| Sep 30, 2025 | 149,000.00 |
| Jun 30, 2025 | 151,000.00 |
| Jun 30, 2025 | 151,000.00 |
| Mar 31, 2025 | 306,000.00 |
| Mar 31, 2025 | 306,000.00 |
| Dec 31, 2024 | 1.08 Mn |
| Dec 31, 2024 | 1.08 Mn |
| Sep 30, 2024 | 132,000.00 |
| Sep 30, 2024 | 132,000.00 |
| Jun 30, 2024 | 128,000.00 |
| Jun 30, 2024 | 128,000.00 |
| Mar 31, 2024 | 122,000.00 |
| Mar 31, 2024 | 122,000.00 |
| Dec 31, 2023 | 120,000.00 |
| Dec 31, 2023 | 120,000.00 |
| Sep 30, 2023 | 119,000.00 |
| Sep 30, 2023 | 119,000.00 |